Metachronous lung cancer resection on extracorporeal membrane oxygenation in a pneumonectomized and mediastinum irradiated patient

Evangelos Koliakos1#, Enrica Chiriatti2#, André Durham1, Michel Gonzalez1, Thorsten Krueger1, Jean-Claude Grange4, Dominique Delay5, Gregoire Gex6, Michel Christodoulou7, Jean Yannis Perentes1,2

1Division of Thoracic Surgery, University Hospital of Lausanne, Lausanne, Switzerland; 2Division of Thoracic Surgery, Centre Hospitalier du Valais Romand, Hôpital de Sion, Sion, Switzerland; 3Division of Radiation Oncology, University Hospital of Lausanne, Lausanne, Switzerland; 4Division of Anesthesiology, 5Division of Cardiothoracic Surgery, 6Division of Pneumologie, Centre Hospitalier du Valais Romand, Hôpital de Sion, Sion, Switzerland

#These authors contributed equally to this work.

Correspondence to: Jean Y. Perentes. Division of Thoracic Surgery, University Hospital of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland. Email: Jean.Perentes@chuv.ch.

Abstract: The management of localized, metachronous, primary non-small cell lung cancer (MP-NSCLC) in pneumonectomized patients is challenging. It generally consists in stereotactic radiation therapy. We report the case of a 57-year-old patient who had a prior history of left pneumonectomy and mediastinal irradiation to manage a central stage IIIA NSCLC. He developed a MP-NSCLC in the middle lobe after 6 years. Stereotactic radiation was judged too risky because of the cumulative dose to the heart and risk of pneumonitis. Pulmonary functions and the cardiovascular evaluation were normal. Multidisciplinary discussions suggested a local treatment for this lesion. The patient underwent a thoracoscopic middle lobe lateral segmentectomy on veno-venous extracorporeal membrane oxygenation (VV-ECMO) support. The patient was extubated and weaned from the ECMO at the end of the case and stayed 24 h at the intensive care unit for surveillance. He was discharged from the hospital on day 4. The histopathological analysis revealed a moderately differentiated NSCLC that was completely resected with no lymph node invasion (pT1N0L0V0Ptn0R0). Twenty-four months after surgery, the patient is alive and disease free. Management of MP-NSCLC in pneumonectomized patients is challenging and should be tailored to each individual case. Extracorporeal life support has helped push the boundaries of patient operability thus extending survival for patients that could previously not be considered for surgery.

Keywords: Pneumonectomy; segmentectomy; extracorporeal membrane oxygenation (ECMO); mediastinal irradiation

Received: 28 May 2020; Accepted: 21 July 2020
doi: 10.21037/vats-2020-lm-03

View this article at: http://dx.doi.org/10.21037/vats-2020-lm-03

Introduction

The management of localized metachronous primary non-small cell lung cancers (MP-NSCLCs) that occur in pneumonectomized patients remains challenging (1). Accepted approaches include stereotactic radiation therapy (SRT), radiofrequency, chemotherapy or surgery. SRT is, in general, the preferred therapeutic modality given its efficacy and lack of important side effects (2). However, in situations of prior mediastinal irradiation, SRT cannot be performed safely and alternative approaches are needed (3). Here we report such a case where a MP-NSCLC was managed surgically with a good perioperative and long-term outcome. We present the following case in accordance with the CARE reporting checklist (available at http://dx.doi.org/10.21037/vats-2020-lm-03).

© Video-Assisted Thoracic Surgery. All rights reserved.
Case presentation

A 57-year-old patient with a past history of stage IIIA NSCLC (epidermoid, ypT3ypN1M0R0) was managed by neoadjuvant chemotherapy, a left pneumonectomy and adjuvant mediastinal irradiation (60 Gy in 30 fractions). One year following surgery, the patient developed 3 lymph node recurrences (2 retroperitoneal and 1 mediastinal) that were managed by stereotactic radiation therapy (SRT, 35 Gy in 5 fractions on each lesion). Six years following the pneumonectomy, the patient had no local/distant recurrence but developed two spiculated lesions in the lateral segment of the middle lobe (Figure 1A) for which bronchoscopy revealed epidermoid carcinoma. A PET-CT showed strong FDG uptake in both lesions but no mediastinal or distant lesions (Figure 1B). Brain MRI showed no metastasis. SRT simulation using CyberKnife® suggested this approach was dangerous because of the mean cumulative irradiation dose delivered to the myocardium and the risk of pneumonitis on a unique lung (Figure 2). Functionally, the patient had an FEV1 of 79% and a diffusion capacity of 73% (% of predicted values). Spiroergometry VO2 max was of 18 mL/kg/min. Following multidisciplinary consent, we decided to perform a VATS middle lobe lateral segmentectomy on veno-venous ECMO (VV-ECMO) support.

Following intubation, the patient received an intravenous bolus of 5,000 U of Heparin and was placed on a jugulo-femoral VV-ECMO using 22F injection jugular and 25F drainage femoral Medtronic cannulas (Figure 3A). The ECMO pump was started and the flow was brought to 4.8 L/min. Throughout the case, we ensured that the activated clotting time was in the range of 200 s. The patient ventilation was interrupted and the tube was disconnected from the ventilator. Transoesophageal echocardiography was performed to ensure the right lung exclusion had no impact on the right ventricular function. We then placed

Figure 1 Pre-operative imaging. (A) CT scan image of both lesions located in the lateral segment of the middle lobe; (B) FDG-PET scan of both lesions located in the lateral segment of the middle lobe. The red circles are placed around the 2 spiculated lesions.

Figure 2 Cumulative dose volume histograms of the radiation therapies, showing a mean cumulative dose to the heart of 25.4 Gy. Red line: heart; Purple line: Right lung.
the patient in the lateral position and performed a lateral middle lobe segmentectomy by VATS combined with mediastinal lymph node sampling (Figure 3B,C). At the end of the surgery, we re-expanded the right lung and started ventilating it again. VV-ECMO was weaned and the patient was drained and extubated. The postoperative course of the patient was uneventful. He was admitted to the intensive care unit for the first night and had a control chest X-ray (Figure 3D). He was mobilized from his bed 6 hours after surgery, was transferred to the ward at 24 hours and was discharged from the hospital on day 3 following chest tube removal.

Histopathological analysis revealed two moderately differentiated epidermoid carcinomas (pT3N0L0V0Pn0R0) with no lymph node invasion. The patient is currently undergoing follow-up with no signs of recurrence 24 months after surgery. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient.

Figure 3 Intraoperative approach and postoperative chest X-ray. (A) VV ECMO implantation in the supine position with lung exsufflation; (B) lateral position view with the thoracoscopic three port approach; (C) peroperative view of the lateral segment resection with both lesions removed; (D) postoperative view of the resected case. VV ECMO, veno-venous extracorporeal membrane oxygenation.

Discussion

Patients treated successfully by surgery for NSCLC remain at risk for second MP-NSCLC (1). In previously resected, non-pneumonectomized patients, the surgical management of MP-NSCLC was shown to be worthwhile with excellent survival results (1). In patients who have previously undergone a pneumonectomy, when applying appropriate selection criteria, sublobar resections seem to provide the best long term outcome (54% OS) with a morbidity of 11% (4). However, most pneumonectomized patients do not have functional parameters allowing the consideration of surgery for a MP-NSCLC. Therefore, while retrospective studies have suggested surgical resection to be worthwhile in well selected cases, most patients are managed by SRT. SRT has become the treatment of choice in patients with localized NSCLCs and bad cardiopulmonary reserve (5). In pneumonecctomized patients, there are only retrospective series that suggest that the approach is safe if the target volume is small with a 2-year survival in the range of 40% to 80% (5). It is, in some situations, possible to perform lung SRT in patients with a prior history of...
mediastinal irradiation (3). However, in the context of pneumonectomy, caution should be taken for this type of approach given that post irradiation pneumonitis can be life threatening (3). In this particular case, care was taken to ensure that the SRT option was well considered. While it would have been possible, our radiation therapy specialists thought it was too risky in regards to the risk of pneumonitis (large irradiation volume because of the dual location) and the close proximity of the myocardium.

To date, surgical approaches of anatomical lung resections in pneumonectomized patients have been reported (6-8). VV-ECMO has allowed to push the boundaries and make the surgeries less invasive and safer. Different approaches using one (Avalon) or two (jugulo-femoral) cannulas were successful with good patient oxygenation and hemodynamic stability during lung resection (6,7). In our case, we chose an approach with two venous cannulas of large diameter permitting sufficient flow. We also had planned to implant an arterial cannula to overcome right ventricular failure that could have occurred with right lung exclusion. Our patient was stable throughout the procedure and the ECMO was weaned and removed at the end of the surgery.

While this case can appear relatively extreme in terms of management, it illustrates the importance of multidisciplinary team management for best therapeutic approaches and long-term outcomes in patients with MP-NSCLC with prior pneumonectomy.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Marcello Migliore and Michel Gonzalez) for the series “VATS in Lung Metastasectomy” published in Video-Assisted Thoracic Surgery. The article was sent for external peer review organized by the Guest Editor and the editorial office.

Reporting Checklist: The authors have completed the CARE reporting checklist (available at http://dx.doi.org/10.21037/vats-2020-lm-03).

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at: http://dx.doi.org/10.21037/vats-2020-lm-03). The series “VATS in Lung Metastasectomy” was commissioned by the editorial office without any funding or sponsorship. MG served as the unpaid Guest Editor of the series. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).

See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


doi: 10.21037/vats-2020-lm-03